
Andrea Cignarella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4703461/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges. Cardiovascular Research, 2022, 118, 988-1003.	1.8	12
2	Targeting of PFKFB3 with miRâ€206 but not mirâ€26b inhibits ovarian cancer cell proliferation and migration involving FAK downregulation. FASEB Journal, 2022, 36, e22140.	0.2	9
3	Gender differences and pharmacological regulation of angiogenesis induced by synovial fluids in inflammatory arthritis. Biomedicine and Pharmacotherapy, 2022, 152, 113181.	2.5	9
4	Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. Aging Clinical and Experimental Research, 2021, 33, 49-56.	1.4	11
5	Estrogen Receptor Functions and Pathways at the Vascular Immune Interface. International Journal of Molecular Sciences, 2021, 22, 4254.	1.8	15
6	Pharmacotherapy of obesity: An update. Pharmacological Research, 2021, 169, 105649.	3.1	28
7	Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacological Research, 2021, 173, 105848.	3.1	16
8	Phagocytosis and inflammation in crystal-induced arthritis: a synovial fluid and in vitro study. Clinical and Experimental Rheumatology, 2021, 39, 494-500.	0.4	1
9	Phagocytosis and inflammation in crystal-induced arthritis: a synovial fluid and in vitro study. Clinical and Experimental Rheumatology, 2021, 39, 494-500.	0.4	5
10	Nonâ€genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells. FASEB Journal, 2020, 34, 12768-12784.	0.2	18
11	Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. International Journal of Molecular Sciences, 2020, 21, 9554.	1.8	15
12	Pharmacologic PPAR-Î ³ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes. Diabetes, 2020, 69, 1562-1572.	0.3	18
13	Sex Differences in the Pro-Angiogenic Response of Human Endothelial Cells: Focus on PFKFB3 and FAK Activation. Frontiers in Pharmacology, 2020, 11, 587221.	1.6	17
14	Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity. International Journal of Molecular Sciences, 2019, 20, 4966.	1.8	21
15	Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients. Endocrine, 2019, 66, 360-369.	1.1	16
16	Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway. Diabetes, 2019, 68, 1303-1314.	0.3	47
17	The continuum of monocyte phenotypes: Experimental evidence and prognostic utility in assessing cardiovascular risk. Journal of Leukocyte Biology, 2018, 103, 1021-1028.	1.5	26
18	The estrogen–macrophage interplay in the homeostasis of the female reproductive tract. Human Reproduction Update, 2018, 24, 652-672.	5.2	32

ANDREA CIGNARELLA

#	Article	IF	CITATIONS
19	Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment. Biochemical Pharmacology, 2018, 154, 414-423.	2.0	13
20	Bisdemethoxycurcumin and Its Cyclized Pyrazole Analogue Differentially Disrupt Lipopolysaccharide Signalling in Human Monocyte-Derived Macrophages. Mediators of Inflammation, 2018, 2018, 1-13.	1.4	5
21	Interplay between gut microbiota and <i>p66Shc</i> affects obesityâ€associated insulin resistance. FASEB Journal, 2018, 32, 4004-4015.	0.2	17
22	Estrogen, Angiogenesis, Immunity and Cell Metabolism: Solving the Puzzle. International Journal of Molecular Sciences, 2018, 19, 859.	1.8	123
23	Convenience versus Biological Significance: Are PMA-Differentiated THP-1 Cells a Reliable Substitute for Blood-Derived Macrophages When Studying in Vitro Polarization?. Frontiers in Pharmacology, 2018, 9, 71.	1.6	180
24	Innate Immunity in Inflammation. , 2018, , 179-190.		1
25	The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 398-407.	1.3	53
26	Structure–Function Relationship Studies In Vitro Reveal Distinct and Specific Effects of Long hain Metabolites of Vitamin E. Molecular Nutrition and Food Research, 2017, 61, 1700562.	1.5	21
27	Shift of monocyte subsets along their continuum predicts cardiovascular outcomes. Atherosclerosis, 2017, 266, 95-102.	0.4	42
28	Upregulation of inducible NO synthase by exogenous adenosine in vascular smooth muscle cells activated by inflammatory stimuli in experimental diabetes. Cardiovascular Diabetology, 2016, 15, 32.	2.7	10
29	Alternative Activation of Human Macrophages Is Rescued by Estrogen Treatment In Vitro and Impaired by Menopausal Status. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E50-E58.	1.8	89
30	Phenotypic activation and pharmacological outcomes of spontaneously differentiated human monocyte-derived macrophages. Immunobiology, 2015, 220, 545-554.	0.8	75
31	Bone Marrow Macrophages Contribute to Diabetic Stem Cell Mobilopathy by Producing Oncostatin M. Diabetes, 2015, 64, 2957-2968.	0.3	85
32	Reduced PMA enhances the responsiveness of transfected THP-1 macrophages to polarizing stimuli. Journal of Immunological Methods, 2014, 402, 76-81.	0.6	94
33	Macrophage Function and Polarization in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1127-1134.	1.1	66
34	Regulation of SIRT1 in Vascular Smooth Muscle Cells from Streptozotocin-Diabetic Rats. PLoS ONE, 2013, 8, e65666.	1.1	20
35	Characterizing and quantifying leukocyte populations in human adipose tissue: Impact of enzymatic tissue processing. Journal of Immunological Methods, 2012, 386, 50-59.	0.6	28
36	Targeting interleukin-1ß hampers atherosclerosis progression – Is there great promise?. Atherosclerosis, 2011, 217, 64-66.	0.4	8

ANDREA CIGNARELLA

#	Article	IF	CITATIONS
37	Vasoprotective activity of standardized Achillea millefolium extract. Phytomedicine, 2011, 18, 1031-1036.	2.3	38
38	Enhancing Endothelial Progenitor Cell Function Through Selective Estrogen Receptor Modulation: A Potential Approach to Cardiovascular Risk Reduction. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2010, 8, 147-155.	0.4	4
39	Mechanisms of estrogen protection in diabetes and metabolic disease. Hormone Molecular Biology and Clinical Investigation, 2010, 4, 575-580.	0.3	13
40	Selective estrogen receptorâ€Î± agonist provides widespread heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action. FASEB Journal, 2010, 24, 2262-2272.	0.2	34
41	Emerging role of estrogen in the control of cardiometabolic disease. Trends in Pharmacological Sciences, 2010, 31, 183-189.	4.0	55
42	Distinct Roles of Estrogen Receptor-α and β in the Modulation of Vascular Inducible Nitric-Oxide Synthase in Diabetes. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 174-182.	1.3	23
43	Animal and cellular models for hypolipidemic drugs. Expert Opinion on Drug Discovery, 2009, 4, 61-69.	2.5	0
44	Effects of androgens on endothelial progenitor cells <i>in vitro</i> and <i>in vivo</i> . Clinical Science, 2009, 117, 355-364.	1.8	33
45	Prolonged Ovarian Hormone Deprivation Impairs the Protective Vascular Actions of Estrogen Receptor αAgonists. Hypertension, 2008, 51, 1210-1217.	1.3	52
46	Gender Differences in Endothelial Progenitor Cells and Cardiovascular Risk Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 997-1004.	1.1	162
47	Increasingly selective pharmacologic targets in cardiovascular disease. Current Atherosclerosis Reports, 2007, 9, 89-90.	2.0	0
48	Hypolipidemic therapy for the metabolic syndrome. Pharmacological Research, 2006, 53, 492-500.	3.1	26
49	Potential pro-inflammatory action of resveratrol in vascular smooth muscle cells from normal and diabetic rats. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 322-329.	1.1	25
50	Selective Agonists of Estrogen Receptor Isoforms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2192-2199.	1.1	46
51	Raloxifene Elicits Combined Rapid Vasorelaxation and Long-Term Anti-Inflammatory Actions in Rat Aorta. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1444-1451.	1.3	14
52	The emerging link between nutrition, inflammation and atherosclerosis. Expert Review of Cardiovascular Therapy, 2006, 4, 385-393.	0.6	10
53	Metabolic syndrome, inflammation and atherosclerosis. Vascular Health and Risk Management, 2006, 2, 145-152.	1.0	113
54	Effect of the ATP-sensitive potassium channel opener ZM226600 on cystometric parameters in rats with ligature-intact, partial urethral obstruction. European Journal of Pharmacology, 2005, 516, 71-77.	1.7	10

#	Article	IF	CITATIONS
55	The Acute Estrogenic Dilation of Rat Aorta Is Mediated Solely by Selective Estrogen Receptor-α Agonists and Is Abolished by Estrogen Deprivation. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1203-1208.	1.3	70
56	Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. Atherosclerosis, 2005, 179, 229-236.	0.4	35
57	Impact of statins on novel risk markers. Cardiovascular Drugs and Therapy, 2003, 17, 361-366.	1.3	2
58	Can we stabilize unstable plaque?. Current Atherosclerosis Reports, 2003, 5, 423-424.	2.0	2
59	Diabetes Undermines Estrogen Control of Inducible Nitric Oxide Synthase Function in Rat Aortic Smooth Muscle Cells Through Overexpression of Estrogen Receptor-β. Circulation, 2003, 108, 211-217.	1.6	46
60	Rupture of the Atherosclerotic Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 535-542.	1.1	107
61	Dietary Mono- and Polyunsaturated Fatty Acids Similarly Affect LDL Size in Healthy Men and Women. Journal of Nutrition, 2002, 132, 715-718.	1.3	56
62	Novel statins: pharmacological and clinical results. Cardiovascular Drugs and Therapy, 2002, 16, 251-257.	1.3	30
63	Direct effects of estrogen on the vessel wall. Medicinal Research Reviews, 2001, 21, 171-184.	5.0	18
64	Gender differences and antioxidant treatment affect aortic reactivity in short-term diabetic rats. European Journal of Pharmacology, 2001, 431, 71-79.	1.7	17
65	ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyteâ€derived macrophages. FASEB Journal, 2001, 15, 1555-1561.	0.2	99
66	Diabetes influences the effect of 17β-estradiol on mechanical responses of rat urethra and detrusor strips. Life Sciences, 2000, 66, 617-627.	2.0	12
67	Diabetes abolishes the vascular protective effects of estrogen in female rats. Life Sciences, 1999, 64, 741-749.	2.0	36
68	Differential Effects of Lovastatin on the Trafficking of Endogenous and Lipoprotein-Derived Cholesterol in Human Monocyte–Derived Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1322-1329.	1.1	29
69	Differential effects of low- and high-dose estrogen treatments on vascular responses in female rats. Life Sciences, 1997, 60, 2291-2302.	2.0	51
70	Downregulation of the Selectin Ligand-Producing Fucosyltransferases Fuc-TIV and Fuc-TVII During Foam Cell Formation in Monocyte-Derived Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1591-1598.	1.1	15
71	NOVEL LIPID-LOWERING PROPERTIES OF VACCINIUM MYRTILLUS L. LEAVES, A TRADITIONAL ANTIDIABETIC TREATMENT, IN SEVERAL MODELS OF RAT DYSLIPIDAEMIA: A COMPARISON WITH CIPROFIBRATE. Thrombosis Research, 1996, 84, 311-322.	0.8	98